AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00419705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroThera® Laser System
Description: Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
Study NCT02750631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triple Therapy
Description: The intervention consists of three interventions: missing a night of sleep, early morning bright lights and sleep phase advance
Study NCT02695069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Random Placenta Margin Incision
Description: A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
Study NCT04577872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: The treatment for the sitting group comprised 8 sessions, with a 1-hour combined pelvic floor muscle training (cPFM-T) session each week in a group and 15 minutes of individual home training, six times a week for a total of 8 weeks of treatment. All training sessions comprised warming-up, gradual muscle strengthening and relaxation exercises. In the study, before and after the training programme, we used a self-administered questionnaire.We measured changes in pelvic floor muscle activity with a vaginal surface electromyographic instrument. We performed the transversus abdominis measurements at the same time as the vaginal measurements and pelvic floor muscle tasks.
Study NCT01548404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection altered between back of arms, abdomen and upper thighs.
Study NCT01548404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection altered between back of arms, abdomen and upper thighs.
Study NCT01905696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine
Study NCT03468088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand grip strengthening
Description: Handgrip strengthening exercises will be added to the experimental group. This exercise is chosen based on literature review of EMG and biomechanical studies. Adjustable heavy grip hand gripper will be used as handgrip resistance at 10 repetitions maximum (RM). The exercise will be performed in standing position the patient's back will be rested in a wall, arm at 30º abduction, 60º abduction 90º abduction \& with 90º ER. In this positions, the patient will be performed 3 sets of 10 squeezes each at a 1-minute interval.
Study NCT03468088 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Ultrasound therapy will be used to treat both groups. Ultrasound will be applied; while the patient will be seated in an adjustable chair with back support, feet on the floor. The chair will be positioned beside a table. The patient's shoulder will be rested on the table beside the body and elbow will be flexed at 90°. A round-headed probe will be used that is put in direct contact with the patient's skin over the shoulder joint. Ultrasound gel will be used on all surfaces of the head in order to reduce friction and assist in the transmission of the ultrasonic waves.
Study NCT02519725 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICU diary
Description: The intervention is the elaboration of an ICU diary by caregivers and families The first pages of the diary is standardized to include an explanation of the purpose of the diary. The diary is maintained by the family and ICU staff. The only instruction given to the families and staff members about diary entries is to refrain from writing about confidential matters that could not be shared among the patients, the staff and the relatives. Staff members are free to express compassion and their hope, or absence thereof, that the patient would recover. Relatives can speak freely with the patients without receiving guidance from the ICU staff. At the minimum, the ICU staff write a brief entry at each weekly staff meeting. For patients discharged to wards and if he can receive the diary, the diary is given to the patient. If the patient died, the diary is given to the family.
Study NCT03952819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum sclerostin
Description: blood samples obtained
Study NCT04322136 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pleurodesis via Video-assisted thoracoscopic surgery
Description: Video-assisted thoracoscopic surgery is a type of key-hole surgery performed under general anaesthetic and usually single lung ventilation by a cardio-thoracic surgeon. This is expected to take about 1 hour. Between one and three ports are used to insert a camera and instruments into the chest cavity. Adhesions can be broken down if present and the lining of the lung (visceral pleura) can sometimes be removed (decortication) to facilitate lung re-expansion. The surgeon can then perform either mechanical abrasion or talc poudrage to induce inflammation and subsequent pleurodesis. A chest drain is left in situ post-operatively and is removed when the fluid draining is below a certain volume depending on local practice.
Study NCT04322136 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Indwelling pleural catheter (with talc pleurodesis if suitable)
Description: Once the indwelling pleural catheter is inserted, the pleural fluid will be evacuated as completely as possible. If the lung fully re-expands, 4-5g of sterile graded talc will be instilled via the IPC. The participant will then be discharged on a daily drainage regimen for 14 days. At review in clinic on day 14, the participant will be assessed for spontaneous pleurodesis (\<50ml drainage on 3 consecutive drainage attempts). If pleurodesis has occurred and there is no residual symptomatic effusion, arrangements will be made for IPC removal. Otherwise the participant will switch to a symptom-guided drainage regimen. If the lung does not fully re-expand following complete fluid evacuation, they will be discharged on a symptom-guided regimen without instillation of talc. The drainage regimen will continue for the duration of the study and beyond if pleurodesis has not occurred and pleural fluid continues to accumulate.
Study NCT01145482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: 20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
Study NCT01145482 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
Study NCT03381872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention for complex lesion
Description: In patients who have complex coronary lesions, PCI will performed using intravascular imaging or angiography only according to the allocated arms~1. Intravascular imaging arm~2. Angiography arm~   * Definition of Complex Lesions~     1. True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size~    2. Chronic total occlusion (≥3 months) as target lesion~    3. PCI for unprotected left main (LM) disease (LM os, body, distal LM bifurcation including non-true bifurcation)~    4. Implanted stent length ≥38mm~    5. Multi-vessel PCI (≥2 major epicardial coronary arteries treated at one PCI session)~    6. Multiple stent needed (≥3 more stent per patient)~    7. In-stent restenosis lesion as target lesion~    8. Severely calcified lesion (encircling calcium in angiography)~    9. Ostial coronary lesion (LAD, LCX, RCA)
Study NCT03381872 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent
Description: All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
Study NCT03381872 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravascular imaging (IVUS or OCT)
Description: IVUS Reference site: Largest lumen, Plaque burden \<50% Stent sizing: By measuring vessel diameter (external elastic membrane) at proximal and distal reference sites. The averaged value of the proximal and distal reference external elastic membrane diameter will be used as stent diameter~OCT Reference site: Most normal looking segment, No Lipidic plaque Stent sizing: \[1\] By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25 mm.~\[2\] By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25 mm.
Study NCT03381872 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-coated balloon
Description: All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
Study NCT02417025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PE
Description: Prolonged Exposure
Study NCT02417025 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PE
Description: Prolonged Exposure
Study NCT03599596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine
Description: Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly until delivery
Study NCT03599596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine
Description: Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets twice before delivery
Study NCT01762488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation of the renal arteries
Description: Catheter-based renal denervation by applying low power radiofrequency to the renal artery using the EnligHTN Catheter, introduced by femoral artery access.
Study NCT01762488 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Renal angiography
Description: Renal angiography by femoral access
Study NCT03320356 — intervention group
Intervention type: OTHER
Intervention: the French version of the Oxford Shoulder Score
Study NCT03159143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (28) is a semi-synthetic taxane which blocks mitosis by preventing microtubule depolymerization. It mediates its actions by binding to a different set of microtubule-associated proteins than paclitaxel. It is administered every 3 weeks as a 30 minute infusion at doses between 60 to 75 mg/m\^2.
Study NCT03159143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Alkylating antineoplastic agent. It is administered on day 1 of each cycle at a dose of 110 mg/m\^2
Study NCT03830021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salt reduction program
Description: Dietary and behavioural change program, led by nutritionists, including low sodium dietary advice; use of aromatic herbs and spices in food instead of salt; motivational activities; food diaries; restrict salty processed foods; eat more fresh foods and seasoning advice; problem solving exercises; digital bulletins; individual counselling reinforced at each clinic visit and shopping counselling at local supermarket.
Study NCT03830021 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy lifestyle program
Description: Participants receive an educational healthy lifestyle program that includes 1) methods to cook healthier and the Mediterranean diet based on a high intake of fresh fruit and, vegetables, beans, grain legumes, lentils, nuts, cereals, and olive oil as source of fat; moderate intake of fish, poultry, yoghurt and cheese, low intake of salt, red meat, processed meats and sugar; 2) physical activity; 3) drink more water and reducing alcohol consumption; and 4) sleep education.
Study NCT04333693 — intervention group
Intervention type: PROCEDURE
Intervention: Vascular surgery
Description: Open vascular, endovascular or hybrid procedures
Study NCT00872547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy ASR™ Hip System
Description: Resurfacing system
Study NCT00872547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy ASR™ XL Head / ASR™ Acetabular Cup System
Description: Large Metal-on-Metal Total Hip Replacement
Study NCT02347709 — intervention group
Intervention type: PROCEDURE
Intervention: Diabetic Foot Ulcer Biopsy
Description: Specimens from both the wound edge and a distal area of skin of patients will be obtained via 3 mm punch biopsy in the Winthrop University Hospital Wound Care Center. Biopsies will be collected from the wound edge prior to routine debridement using the following standard procedures, including the use of anesthetic if needed.
Study NCT02347709 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Study subjects from all three groups will be asked to complete a one-page Focused Neuropathy Evaluation. Providers will complete a one-page Focused Neuropathy Evaluation and a complete neurological examination and sensation assessment.
Study NCT02347709 — intervention group
Intervention type: OTHER
Intervention: Comprehensive Neuropathy Assessment
Description: Standard Monofilament Exam, Vibration Assessment, and Temperature Assessment will be performed on all patients in all study groups.
Study NCT02347709 — intervention group
Intervention type: OTHER
Intervention: Wound Photography
Description: Digital photographs and wound measurements for patients in Study Group 1 will be obtained per standard protocol at baseline and all subsequent visits.
Study NCT06609993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: concentrate of red blood cells
Description: concentrate of red blood cells will be transfused when concentration of haemoglobin \< 10g%
Study NCT06609993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: red blood cells autotransfusion
Description: red blood cells from the operation site will be retransfused using cell saver
Study NCT00533338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Gain Prevention Program
Description: Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling.
Study NCT00533338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Packet of questionnaires will be completed.
Study NCT00533338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Packet of questionnaires will be completed.
Study NCT06609993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primary treatment of postoperative nausea and vomiting (PONV)
Description: dexamethasone ((Dexaven 4mg/ml, Jelfa, Poland) in a dose of 4 mg will be administered intravenously when incidence of PONV is observed
Study NCT01235377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Favor one of two thiazides for new prescriptions & attempt target dose
Description: Providers will be randomized to either Favor Chlorthalidone or Favor Hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. Providers will have agreed to adhere to their assignment for patients for whom there is equipoise, but they are free to deviate if medically indicated for individual patients. There is no requirement to maintain the initial thiazide therapy; it is expected that the regimen may require adjustment over time. The cluster assignment is simply to favor a particular thiazide on initiation of thiazide therapy and attempt to reach the target dose.
Study NCT02466399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POLAT-001
Description: Subconjunctival injection
Study NCT02466399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution
Description: Latanoprost ophthalmic solution q.d., evening
Study NCT02686996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carnosine
Description: Carnosine capsules (2g) twice per day for 14 weeks
Study NCT02686996 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (methylcellulose) capsules for control group identical to intervention capsules and dose
Study NCT01554124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: 40 mg/kg every 8 hours (every 12 hours in the youngest age group: \< 32 weeks GA and \< 2 weeks postnatal age).~Treatment duration = 21 ± 7 days
Study NCT00581217 — intervention group
Intervention type: OTHER
Intervention: Aquacel Ag
Description: Aquacel Ag will be applied to one donor site.
Study NCT00581217 — intervention group
Intervention type: OTHER
Intervention: Glucan II
Description: Glucan II to be applied to a donor site on same patient for comparison
Study NCT01799941 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nuedexta (DM 20 mg/Q 10 mg)
Description: Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
Study NCT01592214 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 4% Klucel® gel formulation, concentration 0, total daily volume 1.8 ml, 3 doses 8 hours apart on Day 1 and 1.2 ml, 2 doses 12 hrs apart on Days 2 to 5.
Study NCT01592214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XF-73 in 2% Klucel gel
Description: XF-73 in a modified 2% Klucel® gel formulation: Part 1, #1: concentration 0.5 mg/g, twice a day in volume 0.3 mL/naris/dose, total dose 0.6 mg; Part 1, #2: 2.0 mg/g concentration, twice a day in volume 0.3 mL/naris/dose, total dose 2.4 mg; Part 2, #1: Concentration 0.5 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 0.9 mg, 2 doses 12 hours apart on Days 2-5, total volume 1.2 ml and total dose 0.6 mg ; Part 2, #2: 2.0 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 3.6 mg, 2 doses 12 hours apart on Days 2-5,total volume 1.2 ml and total dose 2.4 mg.
Study NCT01592214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XF-73 in 4% Klucel gel
Description: XF-73 in a 4% Klucel® gel formulation: Part 2 #3: concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
Study NCT03953742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-200
Description: CPI-200 will be administered via intravenous infusion on Day 1 of a 21-Day cycle
Study NCT01563939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.~Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg.
Study NCT03347591 — intervention group
Intervention type: GENETIC
Intervention: WES
Description: 136 bleeding related OMIM (Online Mendelian Inheritance in Man)-proved genes involved in haemostasis will be selected from Whole Exome Sequencing (WES)
Study NCT03347591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Several assays
Description: Patients will be approached by their own treating physician. Data will be collected through questionnaires, a clinical interview, a blood and saliva sample obtained from each participant, and thorough review of electronic patient records. All procedures are study related. In case a physician visit with the treating physician is already planned, or in case a venepuncture for regular diagnostics or treatment is already planned, this can be combined with the study procedures to prevent an extra visit.
Study NCT01620424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
Study NCT01620424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
Study NCT03496740 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Penile Block
Description: Ultrasound guided dorsal penile nerve block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
Study NCT03496740 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal Block
Description: Nerve stimulation guided bilateral pudendal block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
Study NCT03496740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine (Block Drug)
Description: Block drug
Study NCT01712282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity, 2 x 30 minutes/day
Description: weight-bearing treadmill, pulse reserve increase of 50%
Study NCT02650739 — intervention group
Intervention type: PROCEDURE
Intervention: Macular hole surgery
Description: Vitrectomy with internal limiting membrane removal and gas tamponade
Study NCT03587636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposome bupivacaine
Description: interscalene block with liposomal bupivacaine plus bupivacaine
Study NCT03587636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: interscalene block with bupivacaine